TGFβ1-dependent podocyte dysfunction

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 1, 2013, Pages 93-99

  Herman Edelstein, Michal ^a,b   Weinstein, Talia ^b,c   Gafter, Uzi ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

EMT; foot process effacement; podocyte; Smad; TGF

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

APOPTOSIS; CELL DAMAGE; CELL INTERACTION; CELL MOTILITY; CELL POLARITY; CELL PROLIFERATION; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; PODOCYTE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; APOPTOSIS; CELL DEDIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84871767768     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835b4870     Document Type: Review

References (98)

1. Herman-Edelstein M, Thomas MC, Thallas-Bonke V, et al. Dedifferentiation of immortalized human podocytes in response to transforming growth factorbeta: a model for diabetic podocytopathy. Diabetes 2011; 60:1779-1788.
2. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59:1794-1802.
3. Schnaper HW, Jandeska S, Runyan CE, et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009; 14:2448-2465.
4. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13:2600-2610.
5. Lee HS. Mechanisms and consequences of TGF-b overexpression by podocytes in progressive podocyte disease. Cell Tissue Res 2012; 347: 129-140.
6. Wang B, Koh P, Winbanks C, et al. miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 2011; 60:280-287.
7. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74:991-1003.
8. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108:807-816.
9. Kasuga H, Ito Y, Sakamoto S, et al. Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis. Kidney Int 2001; 60:1745-1755.
10. Murphy SR, Dahly-Vernon AJ, Dunn KM, et al. Renoprotective effects of anti-TGF-beta antibody and antihypertensive therapies in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2012; 303:R57-R69.
11. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220-227.
12. Houlihan CA, Akdeniz A, Tsalamandris C, et al. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002; 25:1072-1077.
13. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-beta(1) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012; 35:483-488.
14. Xu L, Kitani A, Strober W. Molecular mechanisms regulating TGF-betainduced Foxp3 expression. Mucosal Immunol 2010; 3:230-238.
15. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005; 10:48-56.
16. Meng XM, Huang XR, Xiao J, et al. Diverse roles of TGF-beta receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol 2012; 227:175-188.
17. Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, et al. Inhibitory Smad7: emerging roles in health and disease. Curr Mol Pharmacol 2011; 4:141-153.
18. Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009; 297:F1587-F1596.
19. BurnsWC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17:2484-2494.
20. Meng XM, Huang XR, Xiao J, et al. Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 2012; 81:266-279.
21. Warmflash A, Zhang Q, Sorre B, et al. Dynamics of TGF-beta signaling reveal adaptive and pulsatile behaviors reflected in the nuclear localization of transcription factor Smad4. Proc Natl Acad Sci USA 2012; 109:E1947-E1956.
22. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41:263-272.
23. Yan X, Chen YG. Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J 2011; 434:1-10.
24. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008; 13:4984-4992.
25. Ka SM, Yeh YC, Huang XR, et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012; 55:509-519.
26. Leeuwis JW, Nguyen TQ, Chuva de Sousa Lopes SM, et al. Direct visualization of Smad1/5/8-mediated transcriptional activity identifies podocytes and collecting ducts as major targets of BMP signalling in healthy and diseased kidneys. J Pathol 2011; 224:121-132.
27. Kazama I, Mahoney Z, Miner JH, et al. Podocyte-derived BMP7 is critical for nephron development. J Am Soc Nephrol 2008; 19:2181-2191.
28. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293:F1641-F1648.
29. Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front Biosci 2008; 13:4726-4739.
30. De Petris L, Hruska KA, Chiechio S, Liapis H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22:3442-3450.
31. Mason RM. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 2009; 3:95-104.
32. Nystrom J, Hultenby K, Ek S, et al. CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney. Nephrol Dial Transplant 2009; 24:2038-2044.
33. Turk T, Leeuwis JW, Gray J, et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 2009; 57:623-631.
34. Ueda H, Miyazaki Y, Matsusaka T, et al. Bmp in podocytes is essential for normal glomerular capillary formation. J Am Soc Nephrol 2008; 19: 685-694.
35. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17:2504-2512.
36. Xiao HQ, Shi W, Liu SX, et al. Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta 1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats. Clin Exp Pharmacol Physiol 2009; 36:682-689.
37. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012; 18:396-404.
38. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005; 118:3573-3584.
39. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19:128-139.
40. Guo Y, Xiao L, Peng Y, et al. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res 2012; 61:337-346.
41. Schmidt-Ott KM, Barasch J. WNT/beta-catenin signaling in nephron progenitors and their epithelial progeny. Kidney Int 2008; 74:1004-1008.
42. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5:691-701.
43. Dai C, Stolz DB, Kiss LP, et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20:1997-2008.
44. He W, Dai C, Li Y, et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20:765-776.
45. Surendran K, Schiavi S, Hruska KA. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16:2373-2384.
46. Heikkila E, Juhila J, Lassila M, et al. Beta-Catenin mediates adriamycininduced albuminuria and podocyte injury in adult mouse kidneys. Nephrol Dial Transplant 2010; 25:2437-2446.
47. Wang D, Dai C, Li Y, Liu Y. Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int 2011; 80:1159-1169.
48. Kato H, Gruenwald A, Suh JH, et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem 2011; 286:26003-26015.
49. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2010; 22:90-103.
50. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009; 111:9-15.
51. Kistler AD, Altintas MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. Kidney Int 2012; 81:1053-1055.
52. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354:1387-1401.
53. Henique C, Tharaux PL. Targeting signaling pathways in glomerular diseases. Curr Opin Nephrol Hypertens 2012; 21:417-427.
54. Teng B, Lukasz A, Schiffer M. The ADF/cofilin-pathway and actin dynamics in podocyte injury. Int J Cell Biol 2012; 2012:320531.
55. Wang L, Ellis MJ, Gomez JA, et al. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 2012; 81:1075-1085.
56. Hills CE, Squires PE. The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 2011; 22:131-139.
57. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21:1247-1253.
58. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelial- mesenchymal-myofibroblast transition. Kidney Int 2011; 80:41-50.
59. Li Y, Kang YS, Dai C, et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172:299-308.
60. Wang C, Liu X, Ke Z, et al. Mesangial medium from IgA nephropathy patients induces podocyte epithelial-to-mesenchymal transition through activation of the phosphatidyl inositol-3-kinase/Akt signaling pathway. Cell Physiol Biochem 2012; 29:743-752.
61. Samejima K, Nakatani K, Suzuki D, et al. Clinical significance of fibroblastspecific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis. Nephron Clin Pract 2011; 120:c1-c7.
62. Boini KM, Xia M, Xiong J, et al. Implication of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis. J Cell Mol Med 2011; 16:1674-1685.
63. Kang YS, Li Y, Dai C, et al. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 2010; 78:363-373.
64. Ghayur A, Liu L, Kolb M, et al. Adenovirus-mediated gene transfer of TGF-beta1 to the renal glomeruli leads to proteinuria. Am J Pathol 2012; 180:940-951.
65. Toyoda M, Najafian B, Kim Y, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56:2155-2160.
66. Kim J, Sohn E, Kim CS, Kim JS. Renal podocyte apoptosis in Zucker diabetic fatty rats: involvement of methylglyoxal-induced oxidative DNA damage. J Comp Pathol 2011; 144:41-47.
67. Dessapt C, Baradez MO, Hayward A, et al. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant 2009; 24:2645-2655.
68. Liu W, Zhang Y, Hao J, et al. Nestin protects mouse podocytes against high glucose-induced apoptosis by a Cdk5-dependent mechanism. J Cell Biochem 2012; 113:3186-3196.
69. He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007; 18: 93-102.
70. Griffin SV, Petermann AT, Durvasula RV, Shankland SJ. Podocyte proliferation and differentiation in glomerular disease: role of cell-cycle regulatory proteins. Nephrol Dial Transplant 2003; 18 (Suppl. 6):vi8-vi13.
71. Saleem MA, Zavadil J, Bailly M, et al. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol 2008; 295:F959-F970.
72. Kim JH, Kim BK, Moon KC, et al. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003; 64:1715-1721.
73. Patek CE, Fleming S, Miles CG, et al. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet 2003; 12:2379-2394.
74. Shimizu M, Kondo S, Urushihara M, et al. Role of integrin-linked kinase in epithelial-mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant 2006; 21:2380-2390.
75. Rottner K, Stradal TE. Actin dynamics and turnover in cell motility. Curr Opin Cell Biol 2011; 23:569-578.
76. Grgic I, Brooks CR, Hofmeister AF, et al. Imaging of podocyte foot processes by fluorescence microscopy. J Am Soc Nephrol 2012; 23:785-791.
77. Berger K, Moeller MJ. Cofilin-1 in the podocyte: a molecular switch for actin dynamics. Int Urol Nephrol 2011; 43:273-275.
78. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.
79. Faul C, Asanuma K, Yanagida-Asanuma E, et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17:428-437.
80. Garg P, Verma R, Cook L, et al. Actin-depolymerizing factor cofilin-1 is necessary in maintaining mature podocyte architecture. J Biol Chem 2010; 285:22676-22688.
81. Kim EY, Suh JM, Chiu YH, Dryer SE. Regulation of podocyte BK(Ca) channels by synaptopodin, Rho, and actin microfilaments. Am J Physiol Renal Physiol 2010; 299:F594-F604.
82. Lu TC, He JC, Wang ZH, et al. HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J Biol Chem 2008; 283:8173-8182.
83. Mathieson PW. Podocyte actin in health, disease and treatment. Nephrol Dial Transplant 2010; 25:1772-1773.
84. Sistani L, Duner F, Udumala S, et al. Pdlim2 is a novel actin-regulating protein of podocyte foot processes. Kidney Int 2011; 80:1045-1054.
85. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14:931-938.
86. Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22:239-245.
87. Brown EJ, Schlondorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42: 72-76.
88. Cybulsky AV, Kennedy CR. Podocyte injury associated with mutant alphaactinin-4. J Signal Transduct 2011; 2011:563128.
89. Khurana S, Chakraborty S, Lam M, et al. Familial focal segmental glomerulosclerosis (FSGS)-linked alpha-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors. J Biol Chem 2012; 287:12027-12035.
90. Tang VW, Brieher WM. Alpha-Actinin-4/FSGS1 is required for Arp2/3-dependent actin assembly at the adherens junction. J Cell Biol 2012; 196:115-130.
91. Winkler CA, Nelson G, Oleksyk TK, et al. Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. Semin Nephrol 2010; 30:111-125.
92. Bitzan M, Babayeva S, Vasudevan A, et al. TNFalpha pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and beta3 integrin activation. Pediatr Nephrol. [Epub ahead of print]
93. Yu L, Lin Q, Liao H, et al. TGF-beta1 induces podocyte injury through Smad3-ERK-NF-kappaB pathway and Fyn-dependent TRPC6 phosphorylation. Cell Physiol Biochem 2010; 26:869-878.
94. Hsu HH, Hoffmann S, Endlich N, et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med (Berl) 2008; 86:1379-1394.
95. Jiang L, Ding J, Tsai H, et al. Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation. Exp Biol Med (Maywood) 2011; 236:184-193.
96. Krall P, Canales CP, Kairath P, et al. Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease. PLoS One 2010; 5:e12859.
97. Zhang H, Ding J, Fan Q, Liu S. TRPC6 upregulation in Ang II-induced podocyte apoptosis might result from ERK activation and NF-kappaB translocation. Exp Biol Med (Maywood) 2009; 234:1029-1036.
98. Tian D, Jacobo SM, Billing D, et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 2010; 3:147ra77.